Extracellular proTGF-b is covalently linked to ''milieu'' molecules in the matrix or on cell surfaces and is latent until TGF-b is released by integrins. Here, we show that LRRC33 on the surface of microglia functions as a milieu molecule and enables highly localized, integrin-aVb8-dependent TGF-b activation. Lrrc33 À/À mice lack CNS vascular abnormalities associated with deficiency in TGF-b-activating integrins but have microglia with a reactive phenotype and after 2 months develop ascending paraparesis with loss of myelinated axons and death by 5 months. Whole bone marrow transplantation results in selective repopulation of Lrrc33 À/À brains with WT microglia and halts disease progression. The phenotypes of WT and Lrrc33 À/À microglia in the same brain suggest that there is little spreading of TGF-b activated from one microglial cell to neighboring microglia. Our results suggest that interactions between integrin-bearing cells and cells bearing milieu moleculeassociated TGF-b provide localized and selective activation of TGF-b.
In Brief
The cell-surface milieu molecule LRRC33 selectively modulates downstream signaling outcomes through direct association with the TGF-b ligand in specific cell types.
INTRODUCTION
The three transforming growth factor bs (TGF-bs) present in mammals have important roles throughout the body in development and homeostasis, including in the CNS. TGF-b1 organizes responses to neurodegeneration and is constitutively expressed in microglia into adulthood (Kiefer et al., 1995) . Tgfb1 À/À mice die from uncontrolled lymphocyte proliferation and autoimmunity (Robertson and Rifkin, 2016) . Longer-lived Il2-Tgfb1;Tgfb1 À/À mice develop neurological defects and marked microglia alterations (Butovsky et al., 2014) . The TGF-b prodomain ($250 amino acid residues) and growth factor (GF) domain ($110 amino acid residues) are derived from a single gene. At the earliest stage of proTGF-b glycoprotein biosynthesis, in the endoplasmic reticulum (ER), ''milieu molecules'' non-covalently associate with and disulfide link to the TGF-b prodomain. In the Golgi, a pro-protein convertase cleaves between the TGF-b prodomain and GF domain; however, after secretion, the GF maintains tight, noncovalent association with the prodomain and is latent. Previously identified milieu molecules are latent TGF-b binding proteins (LTBPs) and glycoprotein-A repetitions predominant protein (GARP, leucine-rich repeat-containing protein 32, LRRC32). Latent TGF-b complexes with LTBPs 1, 3, and 4 are stored in the extracellular matrix (ECM). Complexes with GARP are stored on the surface of endothelium, platelets, and induced T regulatory cells (Robertson and Rifkin, 2016) . Two integrins, aVb6 and aVb8, bind with high affinity to an arg-gly-asp (RGD) motif in the prodomains of TGF-bs 1 and 3. Binding is not sufficient for activation; application of force by the cytoskeleton to the integrin that is resisted by a milieu molecule linked to the prodomain appears to be required to distort the prodomain, release the GF from the prodomain, and hence activate TGF-b. Thus, stimulation of cells by TGF-b may be localized to the site of TGF-b activation. The importance of integrins in activation of TGF-b1 is emphasized by mutation of the prodomain RGD sequence to arg-gly-glu (RGE), which phenocopies TGF-b1 deficiency (Robertson and Rifkin, 2016) Localized release of TGF-b may explain why it can mediate such a wide range of functions in vertebrates, many of which appear contradictory to one another. Here, we show that molecules that covalently associate with proTGF-b provide unique milieus for activation such that TGF-b can have highly localized effects within tissues. We identify LRRC33 as a milieu molecule that is uniquely associated with, and required for, integrin-dependent activation of TGF-b1 in macrophages and their relatives in the nervous system, microglia. Multiple approaches define highly specific association between LRRC33 and proTGF-b1. Although no previous studies on Lrrc33 À/À (Nrros À/À ) mice have suggested a role in TGF-b1 activation, reported phenotypes (Noubade et al., 2014; Su et al., 2014) are downstream of TGF-b1 dysregulation. Lrrc33 À/À mice appear normal up to 2 months of age but then develop ascending paraparesis that is characterized by demyelination, loss of axons, loss of neurons in the somatomotor cortex and spinal cord, and death by 5 months. Transplantation with wild-type (WT) whole bone marrow arrests disease progression and WT microglia selectively repopulate the CNS. Transcriptional profiling of Lrrc33 À/À microglia demonstrates defective TGF-b1 signaling and concordance with the profile from Il2-Tgfb1;Tgfb1 À/À mice (Butovsky et al., 2014) . Lrrc33 À/À mice have the neurological but not the vascular defects found in mice deficient in TGF-b1 and integrin a V b 8 and suggest that neural-glial and vascular milieus for TGF-b1 activation are separate in the CNS.
RESULTS
Homology and Tissue Expression of LRRC33 and GARP LRRC33 is highly homologous with GARP (34% amino acid sequence identity) and only distantly related to other LRR super-family proteins (Figures 1A and 1B) . Identity between LRRC33 and GARP is comparable to that seen with proteins that associate with related ligands, such as toll-like receptors TLR7 and TLR8 ( Figure 1B ). LRRC33 and GARP each contain a signal sequence, an ectodomain containing 23 LRRs, a transmembrane domain, and a cytoplasmic domain ( Figure 1A ). Cysteine residues 192 and 331 in GARP disulfide link to a Cys in each proTGF-b monomer to form a 1:2 complex (Wang et al., 2012) . Fascinatingly, these Cys residues are conserved in LRRC33 ( Figure 1A , asterisks) and in none of the other LRR family proteins shown in Figure 1B . Lrrc33 expression is largely limited to cells of hematopoietic origin. Among normal and tumor cell lines, Lrrc33 expression is highest in myeloid lineage cells including macrophages and dendritic cells, is also high in B cells, and is generally low in T cells and natural killer (NK) cells (Figures 1C and 1D) . Among normal human tissues, LRRC33 and TGF-b1 mRNA expression correlates ( Figure 1E ). X-gal staining of organs from heterozygotes with a LacZ reporter showed that Lrrc33 was expressed strongly in spleen and at lower levels in thymus ( Figure 1F ). In contrast, little Lrrc33 was expressed in liver, kidney, heart, lung, and skin. In the brain, Lrrc33 was widely and diffusely expressed (Figure 1G) . In contrast, Garp was localized within the frontal cerebral cortex ( Figure 1G ). RNA sequencing (RNA-seq) data on 8 cell populations of validated purity from the brain (Zhang et al., 2014) showed that Lrrc33 is highly expressed in microglia but less in other CNS cell types, in resemblance to TGF-b1 (Figure 1H ; Data S1). In contrast, Garp is highest on pericytes and endothelial cells ( Figure 1H ), in agreement with its presence in blood vessels (Figure 1G, inset) .
ProTGF-b1 Associates with LRRC33 on the Cell Surface Immunoprecipitation (IP) and western blotting (WB) showed highly specific association between LRRC33 and proTGF-b1. IP followed by WB of transfectants showed that proTGF-b1, GARP, and LRRC33 could each be detected in cell lysates when TGF-b1 and milieu molecules were expressed individually or together (Figure 2A ). Furthermore, FLAG-tagged milieu molecules were found to co-associate with proTGF-b1 when the IP was done either with the milieu molecule (first panel) or proTGF-b1 (third panel). Moreover, IP of supernatants from the same transfectants showed that secretion of proTGF-b1 into the supernatant ( Figure 2B , lane 3) was prevented by co-expression with LRRC33 ( Figure 2B , lane 6) or GARP ( Figure 2B , lane 4) (Wang et al., 2012) . Thus, LRRC33 associates with proTGF-b1 and stores it in a cell-associated form, whereas in absence of a milieu molecule, proTGF-b1 is secreted.
Non-reducing SDS-PAGE showed that LRRC33 was disulfide linked to proTGF-b1. Whereas proTGF-b1 migrated at 75-100 kDa in non-reducing SDS-PAGE ( Figure 2C , lane 2), WT LRRC33 co-expression shifted the mass of proTGF-b1 immunoreactive material to 270-290 kDa ( Figure 2C , lane 3). C200 and C344 in LRRC33 are homologous to the cysteines in GARP that disulfide link to proTGF-b1 ( Figure 1A ). The LRRC33 C200A and C344A single mutants and C200A/C344A double mutant were expressed at similar levels as WT LRRC33 in 293T cells ( Figure 2C , third panel). Single cysteine mutations did not abolish disulfide formation but slowed migration in SDS-PAGE ( Figure 2C , upper two panels, lanes 4 and 5 compared to 3), as expected from greater elongation in SDS after removal of one disulfide crosslink (Wang et al., 2012) . In contrast, the C200A/C344A double mutant failed to disulfide crosslink to proTGF-b1 ( Figure 2C , panels 1 and 2, lane 6). Thus, LRRC33 disulfide links to proTGF-b1 and uses cysteines homologous to those in GARP to do so (Wang et al., 2012) .
The specificity of association between LRRC33 and proTGF-b1 was further tested by competition with LTBP and GARP, which are highly validated partners of proTGF-b1 (Robertson and Rifkin, 2016) . Impressively, LRRC33 outcompeted LTBP for proTGF-b1 ( Figure 2D , lane 8), despite the ability of LTBP to covalently link to proTGF-b1 in the absence of LRRC33 ( Figure 2D , lane 5). GARP and LRRC33 competed (B) were immunoprecipitated (IP) and subjected to reducing SDS 10% PAGE and blotted (WB) as indicated. (C) Disulfide linkage. 293T cells transfected with indicated constructs were subjected to IP, 7.5% non-reducing or 10% reducing SDS-PAGE, and WB as indicated.
(D) LRRC33 outcompetes LTBP for proTGF-b1. 293T transfectant lysates were IP, subjected to non-reducing SDS 7.5% PAGE, and WB as indicated. Dotted line divides samples prepared identically, blotted separately, and imaged identically. (E) LRRC33-proTGF-b1 complex in THP-1 cells. THP-1 cells were treated with or without PMA (80 nM, 24 hr) and cell lysates were IP with 1/8.8 to LRRC33 or mouse immunoglobulin G (IgG) control, reducing and non-reducing SDS 7.5% PAGE, and WB as indicated. (F) Flow cytometry. THP-1 cells treated with or without PMA were stained with anti-LRRC33 (1/8.8), anti-prodomain (TW4-2F8), anti-integrin a V (17E6), or antiintegrin b 6 (7.1G10) and subjected to fluorescence-activated cell sorting (FACS). Numbers in histograms show specific mean fluorescence intensity.
(G) Blockade of active TGF-b1 release. THP-1 cells treated with or without PMA were incubated with antibody 1/8.8 to LRRC33, 17E6 to a V integrin, or MAB240 to TGF-b1 and cocultured with TMLC to measure TGF-b activation. Data represent mean ± SEM of quadruplicate samples. See also Figure S1 . , and Lrrc33 À/À mice. Data are mean ± SEM. p values for last time point (*, < 0.05; ****, < 0.0001) are from unpaired Student's t test (B-D) and log-rank test (E) . (legend continued on next page) equally with one another for proTGF-b1 ( Figure 2D , lane 7), and as previously described (Wang et al., 2012 ) GARP outcompeted LTBP ( Figure 2D , lane 6). Thus, LRRC33 completely outcompetes the highly specific association of LTBP with proTGF-b1. Myeloid cells and cell lines express TGF-b1 (Khalil et al., 1989; Taipale et al., 1994) but a corresponding milieu molecule has not been defined. The myelomonocytic cell line THP-1 expresses Lrrc33 and Tgfb1 mRNA ( Figure 1D ) and phorbol myristyl acetate (PMA) increases Tgfb1 mRNA (Taipale et al., 1994) . We made mAb 1/8.8 specific to human LRRC33 ( Figure S1 ). IP of THP-1 cell lysates with LRRC33 mAb and WB with anti-TGF-b1 prodomain demonstrated a PMA-stimulated increase in the LRRC33-proTGF-b1 non-reduced complex at 290 kDa and an LRRC33-associated reduced proTGF-b1 monomer at 48 kDa ( Figure 2E ). Importantly, LRRC33 and proTGF-b1 were present on the cell surface and their expression was increased by PMA ( Figure 2F ). In contrast, expression of the a V and b 6 subunits of a V b 6 integrin, which can activate TGF-b1 (Robertson and Rifkin, 2016) , were little affected by PMA stimulation ( Figure 2F ).
We next determined whether LRRC33 and a V integrins participated in TGF-b1 activation in THP-1 cells. PMA stimulation greatly increased TGF-b1 activation ( Figure 2G ). Activation was inhibited by 1/8.8 antibody to LRRC33 and 17E6 antibody to integrin a V (Mitjans et al., 1995) , and specificity was demonstrated via inhibition by antibody to TGF-b1 ( Figure 2G ). Thus, LRRC33 specifically associates with and is disulfide linked to proTGF-b, is co-expressed with proTGF-b1 on the cell surface, and plays a role in TGF-b activation.
Deficiency of Lrrc33 in Mice Results in Ascending Paraparesis
Mice with heterozygous deficiency of Lrrc33 ( Figure S2A ) were fertile and healthy. Homozygous Lrrc33 À/À mice showed increased susceptibility to respiratory tract infection, were sometimes runted (Figures 3A and 3B) , and had a yield at weaning of $20% compared to the Mendelian expectation of 25% but otherwise appeared normal. By 2 months of age, Lrrc33 À/À mice began to display neurological symptoms including defects in motor control and strength, an increase in locomotor activity and exploration, and declining ability to maintain themselves on a rotating cylinder ( Figures 3C and S3A ). Lrrc33 À/À mice developed ascending paraparesis with progressive loss of hind limb grasp, hind limb coordination, bladder control, and ability to right themselves. Eventually, quadriplegia required euthanasia ( Figure 3D ). Lack of bladder control correlated with palpable, highly distended bladders and a failure of reflex urination upon euthanasia (Figure S3B ). All Lrrc33 À/À mice required euthanasia or died by 150 days ( Figure 3E ). Progressive paraparesis was associated with loss of myelin and axons in the spinal cord and brainstem. Spinal cord sections of 4-to 5-month-old Lrrc33 À/À mice stained with H&E showed specific loss of cellularity in the dorsal column paired with appearance of lipid-laden (foamy) macrophages ( Figure 3F ). Bielschowsky silver and Luxol fast blue stains revealed depletion of axons and myelin, respectively, in the same region ( Figure 3F ). Axons and myelin were also depleted in the corticospinal tract of the brain stem ( Figure 3G ), through which motor neuron axons pass from the cerebral cortex to the spinal cord. Although TGF-b1 deficiency results in uncontrolled autoimmunity, no autoimmune-like infiltration of the CNS by mononuclear cells or T cells was observed by H&E staining and anti-CD3 immunohistochemistry, respectively. All neonates deficient in the integrin aV or b8 subunits have grossly visible intracerebral hemorrhage, which is also evident in excised brains (Mobley et al., 2009 Figure 3J ) with some mice showing striking patches of neuron loss ( Figure S4A ). Localized decreases in myelin and axon density were also significant in the granule cell layer of the cerebellum ( Figures 3K and  3L ). Losses were much smaller in the somatosensory cortex, with significance reached only for myelin volume ( Figure S4C ). Losses of neurons, myelin, and axons in Lrrc33 À/À mice provide a cellular mechanistic basis for impaired motor coordination and ascending paraparesis.
Abnormalities in Microglia, Macrophages, and TGF-b1 in
Staining for Lrrc33 expression with anti-LacZ in the cerebral cortex of Lrrc33 +/LacZ mice and co-staining with anti-Iba1 to mark microglia (Butovsky et al., 2014) showed that Lrrc33 was expressed in microglia ( Figure 4A microglia demonstrated an altered, activated morphology with fewer cellular processes that were thicker, less ramified, and did not extend as far into their cellular (H-L) Fluorescent immunostaining (upper two rows) with quantitation (lower row) of 40 mm sagittal sections at 4 months of somatomotor cortex region M1 (H-J) and cerebellum (K and L). M (molecular) and II/III mark layers of the cerebral cortex. G marks granule cell layer and dashed lines demarcate the Purkinje cell layer in cerebellum. Scale bars, 100 mm. Quantitation in lower row shows mean ± SEM for three mice from measurements averaged over 2-3 sections per mouse with 1-2 images per section. *p < 0.05; **p < 0.01; ***p < 0.001, unpaired t test. See also Figures S2, S3 , and S4. neighborhoods (Figures 4B and 4C; Videos S1 and S2) . By CD68 immunoreactivity and morphology (Schafer et al., 2012) , Lrrc33 À/À microglia were significantly more reactive-like than WT microglia ( Figure 4D ). We further characterized microglia immunophenotype by flow cytometry by gating on CD45 low , Mac1 + , and CD39 high cells to exclude CD39 neg/low monocytes/ macrophages (Butovsky et al., 2014) . Because CD45 and other markers are upregulated in immune-reactive microglia during viral infection (Sedgwick et al., 1991) , we compared CD45, Mac1, and CD39 as well as CD68 for expression on WT and Lrrc33 À/À microglia. Lrrc33 À/À microglia from multiple mice had statistically significantly increased CD45 and CD68 expression (Figures 4F and 4G) , consistent with the reactive-like phenotype seen in tissue sections with immunohistochemistry. Interestingly, compared to WT, Lrrc33 À/À microglia also showed significantly increased expression of CD39 and decreased expression of Mac1 ( Figure 4G ). Loss of LRRC33 also affected TGF-b1 expression. As predicted by dependence on one another for LRRC33 and proTGF-b1 surface expression on transfectants ( Figure S1 ), WT, but not Lrrc33 À/À , peritoneal exudate cell (PEC) macrophages expressed proTGF-b1 on the cell surface ( Figure 4H ). In contrast, staining of permeabilized cells showed that intracellular proTGF-b1 is present in both WT and Lrrc33
macrophages. Thus, LRRC33 is required for expression of proTGF-b1 on the surface of macrophages. WB of WT PEC lysates showed a high-molecular-weight proTGF-b1 complex of the same size as in cells co-transfected with LRRC33 and proTGF-b1 ( Figure 4I , lanes 1 and 2). In contrast, Lrrc33 À/À PEC lacked a corresponding high-molecular-weight proTGF-b1 complex and instead expressed aberrantly large amounts of uncomplexed proTGF-b1 ( Figure 4I , lane 3). Similarly, IP of PEC with anti-proTGF-b1 followed by WB with anti-proTGF-b1 showed the high MW complex in WT PEC and lack of the high MW complex and the presence of large amounts of aberrant proTGF-b1 in Lrrc33 À/À PEC ( Figure 4J , upper two panels). Moreover, IP with anti-proTGF-b1 followed by WB with an antibody specific for denatured mouse LRRC33 (Noubade et al., 2014) showed LRRC33 associated with proTGF-b1 in WT but not Lrrc33 À/À PEC ( Figure 4J , lower panel).
LRRC33 is detected as two bands of 120 and 90 kDa in WT and not Lrrc33 À/À lysates ( Figure 4J , lower panel). Only the 120 kDa LRRC33 band was present on the cell surface (Figures S5B and S5C) , suggesting that the 120-and 90-kDa bands represent mature LRRC33 with complex N-glycans and immature LRRC33 with high mannose glycans, respectively. After IP from PEC and spleen lysates with anti-proTGF-b1, WB with anti-denatured LRRC33 detected a non-reduced, $290 kDa LRRC33-proTGF-b1 complex from WT but not Lrrc33 À/À cells ( Figure 4K ). Thus, LRRC33 and proTGF-b1 specifically associate and disulfide link to one another in macrophages and spleen cells from WT and not Lrrc33 À/À mice, and proTGF-b1 is aberrant in Lrrc33 À/À macrophages.
We then tested the requirement of LRRC33 and integrins for TGF-b1 activation. Production of active TGF-b1 by WT or Lrrc33 À/À (KO) macrophages or 1:1 mixtures of WT astrocytes with WT or Lrrc33 À/À microglia was greatly decreased with Lrrc33 À/À compared to WT macrophages or microglia (Figure 4L) . SMAD 2/3 phosphorylation was also significantly decreased in Lrrc33 À/À compared to WT microglia ( Figure 4M ), demonstrating canonical TGF-b signaling. Astrocytes express aVb8 and not aVb6 (Zhang et al., 2014) ( Figure 1H ). We used aVb6 and aVb8 inhibitors to test the integrin dependence of TGF-b1 activation in astrocyte: microglia cocultures. Blocking antibody ADWA-2 to aVb8 and a protein that blocks ligand binding to both aVb6 and aVb8 (b6+b8_BP) but not a blocking protein selective for aVb6 (b6_BP) significantly inhibited TGF-b activation in astrocyte cocultures with WT microglia ( Figure 4N ). Thus, activation of TGF-b was dependent on both LRRC33 and aVb8. Overall, the results show that LRRC33 specifically associates with and disulfide links to proTGF-b1 in WT myeloid cells, that proTGF-b1 is intracellular and aberrant in Lrrc33 À/À macrophages, that LRRC33 is required for expression of proTGF-b1 on the surface of macrophages, that LRRC33 is required for activation of TGF-b and phosphorylation of SMAD2/3 in macrophages and astrocyte:microglia cocultures, and that activation of TGF-b is dependent on integrin aVb8 and not aVb6 in astrocyte:microglia cocultures. These results provide mechanistic insight into the aberrant, reactive phenotype of microglia in the CNS of Lrrc33 À/À mice.
Microglia Repopulation and Arrest of Disease Progression by Bone Marrow Transplantation of
Whole bone marrow (wBM) transplantation has been effective in rescuing microglia-related CNS pathologies (Wirenfeldt et al., 2011) . We utilized the CD45.1 and CD45.2 alleles in congenic mice to distinguish donor and recipient BM-derived cells. Whole BM cells (8 3 10 6 ) freshly harvested from 10-week-old mice were intravenously transplanted into lethally irradiated recipients in all four possible Lrrc33 À/À and Lrrc33 +/+ combinations. Mice were neurologically scored as in Figure 3D and sacrificed 5 months post-transplantation to determine donor cell contribution to the (J and K) Lysates from WT and Lrrc33 À/À PEC and spleen cells, LRRC33 (33-G-X5) proTGF-b1 co-transfectants (Tra.), or untransfected cells (Non-tra.) were immunoprecipitated with prodomain antibody TW7-16B4 or mouse IgG coupled to Sepharose and subjected to non-reducing or reducing SDS 7.5% PAGE and WB with anti-denatured mouse LRRC33 (Noubade et al., 2014) Including CD39 high as a sort criterion excluded donor-derived CD39 neg/low monocytes/macrophages that might have also engrafted into recipient mouse brains. Microglia chimerism was expressed as percentage of total ( Figure 5F ) or microglia recovered per brain ( Figure 5G ). There was little chimerism in WT recipients transplanted with either WT wBM (4.1% ± 1.4%) or Lrrc33
wBM (2.4% ± 0.65%). In marked contrast, Lrrc33 À/À mice transplanted with WT wBM showed significantly higher levels of donor-derived microglia (68% ± 16%, p = 0.007; Figure 5F ) and increased total number of microglia ( Figure 5G Figure 5I ) as found in untransplanted mice ( Figure 4G ). Interestingly, for all three markers, donor Lrrc33 À/À microglia, which were outnumbered 40-fold by host WT microglia, showed a minor subpopulation with the fluorescence intensity of WT microglia and a major subpopulation with intensity similar to host Lrrc33 À/À microglia but slightly shifted toward WT intensity ( Figures 5H and S6K ). Differences between donor and host Lrrc33 À/À microglia reached significance for CD39
and Mac1 ( Figure 5I Figures 6A and S7A ). Both WT and Lrrc33 À/À cell populations expressed markers previously found to be selective microglia-specific markers including CD39 (Butovsky et al., 2014) . Previously, 354 genes were found to be selectively expressed in microglia compared to macrophages, and 62 of these were found to differ in expression more than 5-fold between WT and Il2-Tgfb1;Tgfb1 À/À microglia (Butovsky et al., 2014) . Up or downregulation of these 62 genes was completely concordant between Il2-Tgfb1;Tgfb1 À/À microglia and Lrrc33 À/À microglia ( Figure 6B , concordance bar). This concordance strongly suggests that Lrrc33 is required for Tgfb1 signaling in microglia and further suggests that LRRC33 is the only milieu molecule required for TGF-b1 function in microglia.
Gene set enrichment analysis (GSEA) examines sets of genes that function together in key biological processes and show coordinate differential expression (Subramanian et al., 2005) . Quite strikingly, among 50 biological pathways, ''TGF-b signaling'' was the most statistically enriched pathway in WT microglia compared to Lrrc33 À/À microglia ( Figures 6C, 6D , S7C, and S7D), providing independent evidence that LRRC33 is required for TGF-b signaling in microglia. GSEA further revealed significant negative enrichment scores (ESs) (enrichment in Lrrc33
relative to WT microglia) for ''interferon-a response'' and ''interferon-g response'' pathways ( Figure 6D ). Enrichment of these pathways suggests activation of Lrrc33 À/À microglia. Lrrc33
À/À microglia were also significantly enriched for ''E2F targets,'' ''G2M checkpoint,'' and ''mitotic spindle'' ( Figure 6D ), which are all associated with cell cycling. GSEA thus provided independent, hypothesis-free support for the requirement of LRRC33 for TGF-b signaling in microglia and for the reactive phenotype of Lrrc33 À/À microglia.
DISCUSSION

Restriction of LRRC33, Pleiotropy of TGF-b, and Prior Reports
We have established that LRRC33 is a milieu molecule that associates highly specifically with proTGF-b1 and is required for activation of latent TGF-b in macrophages and microglia. LRRC33 functions analogously to LTBPs 1, 3, and 4 and GARP (LRRC32), which are expressed by other cell types (Robertson and Rifkin, 2016) . We propose the term milieu molecule for all such partners of proTGF-b. Macrophages have long been known to be important biological sources of TGF-b (Khalil et al., 1989) ; however, despite investigations (Taipale et al., 1994) a corresponding milieu molecule was not defined until now. Previous publications on LRRC33 have proposed other functions. The hypothesis for a relationship to TLRs emerged from common content of LRRs (Liu et al., 2013) ; however, sequence identity between LRRC33 and TLRs is too low at 15%-18% to suggest a functional relationship, in contrast to the 34% identity of LRRC33 with GARP ( Figure 1B) . Sequence relationship between GARP and LRRC33 has previously been pointed out and they have been given similar gene names: Lrrc32 (Garp) and Lrrc33 (GARP-like 1; Garpl1) (Dolan et al., 2007) . More recently, Lrrc33 was proposed to be renamed Nrros by one group (Noubade et al., 2014) . The hypothesis that LRRC33 negatively regulated reactive oxygen species arose from the observation that combined treatment of macrophages with interferon-g (IFN-g) and lipopolysaccharide (LPS) increased reactive oxygen species and decreased Lrrc33 expression. However, many other genes were similarly downregulated, the oxidase component Cybb was already known to be positively regulated by these agents and sufficed to explain the effect, and, contrary to the hypothesis, no difference was seen between Lrrc33 À/À and WT macrophages in ROS generation either with or without combined LPS and IFN-g treatment (Noubade et al., 2014) . Two previous publications reported no neurological phenotype in Lrrc33 À/À mice (Noubade et al., 2014; Su et al., 2014) ;
hence, we were initially apprehensive of the reception of the findings described here. However, one of these groups recently reported a neurological phenotype similar to that described here, and abnormalities in Lrrc33 À/À microglia; however, this group did not link the defect to TGF-b signaling and was unsuccessful in halting disease progression with BM transplantation (Wong et al., 2017) . Strikingly, the neurological phenotype was not reversed in Lrrc33
;Cybb À/À mice that lacked the ability to generate reactive oxygen species. This finding strongly suggests that Lrrc33 does not function in the ROS pathway, in agreement with the lack of effect on ''reactive oxygen species'' in GSEA ( Figure S7C ), and supports retaining the name Lrrc33 rather than renaming to Nrros. As TGF-b is pleiotropic, multiple downstream effects of LRRC33, which is required for TGF-b activation from macrophages and microglia, are to be expected. We found that expression of 348 genes was significantly altered in Lrrc33 À/À microglia.
Weak, 1.5-to 2-fold effects on ROS in certain assays with Lrrc33 À/À macrophages (Noubade et al., 2014) can be explained by inhibition by TGF-b of ROS generation by macrophages (Tsunawaki et al., 1988) . Findings on TLR signaling (Su et al., 2014) can be explained by downregulation by TGF-b of innate immune signaling (Flavell et al., 2010) including IFN-g signaling in microglia (Zhou et al., 2015) in agreement with our finding with GSEA of enhanced IFN-a and IFN-g signaling in Lrrc33 À/À microglia.
Molecular and Cellular Function of LRRC33
Our study demonstrated that association between LRRC33 and TGF-b1 is exquisitely specific and is required for cell-surface expression of the LRRC33-TGF-b1 complex and TGF-b signaling. Coimmunoprecipitation (CoIP) demonstrated association between proTGF-b1 and LRRC33 in human and mouse myeloid cells and in transfectants that expressed mouse and human proteins. Moreover, a covalent, disulfide-linked, high MW LRRC33-proTGF-b1 complex was demonstrated in all of these cell types. Specificity was further demonstrated because only two of 15 LRRC33 ectodomain cysteines were required for covalent linkage to proTGF-b1 and these corresponded to the two in GARP required for disulfide linkage to proTGF-b1. As additional proofs of specificity, LRRC33, like GARP, prevented secretion of aberrant TGF-b1 and out-competed LTBP in formation of covalent complexes with proTGF-b1. In yet further proofs of specificity, LRRC33 and proTGFb associated with one another on the mice and the stronger expression of TGF-b2 and TGF-b3 than TGF-b1 in early development (Butovsky et al., 2014; Kiefer et al., 1995) . We found little spinal cord pathology in 3-month-old Lrrc33 À/À mice ( Figures S4E and S4F ). Another group examined spinal cords at 15 weeks and reported no loss of axons or myelination (Wong et al., 2017). We found that ascending paraparesis was associated with localized loss of myelin and axons in the cerebellum and within the M1 motor region cortex at 4 months, and with profound loss of myelin and axons in the corticospinal tract and spinal cord at 4.5 months. These regions are associated with motor function. Myelination occurs largely in the first 2 months after birth in mice. The relatively late appearance of symptoms in Lrrc33 À/À mice may relate to important trophic and homeostatic functions of microglia in the CNS, including in phagocytosis, synapse pruning, and interactions with neurons, astrocytes, and myelin-producing oligodendrocytes (Bilimoria and Stevens, 2015; Wirenfeldt et al., 2011) . Lrrc33 À/À Iba1 + microglia had a reactive phenotype evidenced by less ramified morphology, CD45 and CD68 upregulation, and transcriptional upregulation of pathways for IFN-a and IFN-g signaling and cell cycling. Lrrc33 À/À microglia also showed increased CD39 and decreased Mac1 expression. CD4 and CD45 are both increased in reactive microglia (Sedgwick et al., 1991) ; microarrays showed a 19-fold increase in CD4 in Lrrc33 À/À microglia (arrow, Figure S7A ). Measurement of TGF-b in microglia astrocyte co-cultures, GSEA, and phospho-SMAD staining showed that Lrrc33 À/À microglia were deficient in TGF-b activation and signaling. Because TGF-b downregulates microglia reactivity (Liu et al., 2016; Zhou et al., 2015) , the reactive phenotype is likely a direct consequence of the lack of the LRRC33-proTGF-b1 complex required for integrin and force-dependent TGF-b activation (Robertson and Rifkin, 2016) . Remarkably, transplantation with WT wBM rescued a large portion of Lrrc33 À/À mice from disease progression and extended survival to 8 months of age when animals were sacrificed for analysis. Survival of transplanted Lrrc33 À/À mice receiving WT wBM was associated with appearance of much greater numbers of microglia in the CNS of donor origin (68% ± 16%) than in WT mice receiving WT or Lrrc33 À/À wBM (4.1% ± 1.4% and 2.4% ± 0.65%, respectively). Lrrc33 is specifically expressed in microglia within the CNS, and microglia are the only known hematopoietic- 
Activation of TGF-b in Cellular Milieus
Milieu molecules can function on multiple levels to provide highly selective and localized activation of TGF-b. They enable TGF-b to be recognized on the plasma membrane of specific cells (LRRC33 and GARP) or within extracellular matrices (LTBPs) or on different cell types, e.g., LRRC33 on microglia and macrophages or GARP on endothelium and pericytes. Furthermore, because milieus differ in expression of adhesion and chemoattractant molecules, they will attract distinctive cells that bear TGF-b-activating integrins. When the integrin-bearing, TGFb-activating cell is distinct from the cell that secretes proTGF-b into the matrix or displays proTGF-b on the cell surface, TGF-b activation requires two distinct cell types (Figure 7 ). This requirement enables great cellular selectivity in TGF-b activation in much the same way that the three-step model for leukocyte emigration from the blood stream enables selectivity. Of further importance, milieu molecules enable localization of TGF-b activation to the interface between an integrin-bearing activating cell and another cell or matrix bearing the proTGF-b-milieu molecule complex. In contrast, many other members of the TGF-b family such as bone morphogenetic proteins diffuse over long distances to establish morphogenetic gradients (Robertson and Rifkin, 2016) . The close similarity in CNS phenotypes and microglia transcriptional profiles in Tgfb1 and Lrrc33-deficient mice strongly suggests that LRRC33 is the only milieu molecule important for TGF-b1 activation in microglia. Il2-Tgfb1; Tgfb1 À/À mice develop motor abnormalities at 3-4 months and show rotarod deficits, and paralysis steadily progresses until death by 6 months (Butovsky et al., 2014) . Furthermore, all 62 up-and downregulated genes reported in Il2-Tgfb1; Tgfb1 À/À microglia were concordantly regulated in Lrrc33 À/À microglia.
Despite characterization of the phenotypes in mice of knockouts of milieu molecules including LTBPs 1 and 3, GARP, and each of the three TGF-bs (Robertson and Rifkin, 2016; Wu et al., 2017) , the clear correspondence between the neurological phenotypes of Tgfb1 and Lrrc33 deficiency reported here, and comparisons to the phenotypes of knockouts of TGF-b-activating integrins described in the following paragraphs, provide the first compelling evidence for the existence of distinctive milieus that can make TGF-b activation highly localized within tissues (Figure 7) . Association of LTBPs and GARP with multiple proTGFbs, and some redundancy among milieu molecules, may contribute to the difficulty of teasing out the importance of specific milieu molecules for each of the functions of the three TGF-b isoforms (Robertson and Rifkin, 2016; Wu et al., 2017) . Sorting out milieu molecule functions in white blood cell lineages is easier, because these cells express TGF-b1 and not TGF-b2 or b3, and LRRC33 is expressed selectively in these lineages.
Integrating current and previous results in mice with deficiencies in TGF-b activation with transcriptomics data enables us to propose a model for milieu-dependent TGF-b1 signaling in the CNS (Figure 7) . RNA-seq of CNS cell populations of validated purity (Zhang et al., 2014) shows that proTGF-b1 and LRRC33 are each most highly expressed within microglia and that microglia express much less GARP or LTBPs than other CNS cell populations ( Figure 1H ), in agreement with our conclusion that LRRC33 is the sole milieu molecule required for TGF-b1 activation in microglia. Among genes encoding TGF-b-activating integrins, none of the profiled cells express the Itgb6 gene for the integrin b6 subunit, whereas Itgav and Itgb8, which encode the subunits of integrin a V b 8 , are well expressed on oligodendrocyte precursor cells, newly formed oligodendrocytes, and astrocytes, but not on microglia ( Figure 1H ). These transcriptomic results are in excellent agreement with our observation that TGF-b activation in microglia astrocyte co-cultures is dependent on integrin a V b 8 and not a V b 6 .
Mice mutant for Itgav and Itgb8 exhibit neurological defects similar to those of Lrrc33 À/À mice, as well as CNS hemorrhagic defects not shared with Lrrc33 À/À mice, supporting separate neuronal-glial and vascular milieus for TGF-b activation in the CNS (Figure 7) . Itgb8 À/À mice develop neurological phenotypes including ascending paraparesis and ataxia that progress until death by 5 months (Aluwihare et al., 2009; Mobley et al., 2009 coordination by 2-3 months, progress to severe paraparesis, and show both glial and axonal degeneration in the spinal cord (McCarty et al., 2005) . The results on Itgav, Itgb8, Lrrc33, and Tgfb1-deficient mice together with the transcriptional profiles of CNS cell types ( Figure 1H ) and our results showing Lrrc33-dependent and integrin a V b 8 -dependent TGF-b activation in microglia: astrocyte co-cultures provide strong support for the hypothesis that interactions in the milieu between integrin a V b 8 -bearing neural cells and proTGF-b1-LRRC33-microglia are required for maintenance of the integrity of myelinated axons (Figure 7) . CNS vascular defects in mice mutant for Itgav and Itgb8 suggest an additional, Lrrc33-independent milieu for TGF-b activation. Itgav À/À and Itgb8 À/À mice show brain-specific hemorrhage and vascular abnormalities at birth (Aluwihare et al., 2009; McCarty et al., 2005; Mobley et al., 2009 ). In contrast, cerebral hemorrhage was never grossly evident in Lrrc33 À/À neonates or their excised brains or brain sections. Conditional Itgav À/À mutations show that CNS vascular development requires a V integrin in neural cells but not in endothelial cells. Astrocytes express the subunits for integrin a V b 8 ( Figure 1H ). Astrocytes, pericytes, and endothelium express all three TGF-b isoforms together with LTBP1 and LTBP3, while pericytes and endothelium additionally express GARP ( Figure 1H ). Both microglia and blood capillaries are widely distributed throughout the brain and are typically within a cell diameter or so of one another. Nonetheless, the severe effects of Lrrc33 deficiency on microglia and neurologic function with an absence of hemorrhage in the CNS suggest that the microglia-neural cell milieu and the astrocyte-pericyte-endothelium vascular milieu are functionally distinct milieus for TGF-b activation in the CNS. The distinct immunophenotypes of co-existing Lrrc33 À/À host and WT donor microglia also suggest that TGF-b activation is highly localized within the microglia-neural cell milieu. Only when WT host microglia were in large excess over Lrrc33 À/À donor microglia was slight correction of the Lrrc33 À/À immunophenotype seen. These results suggest that there is little spreading of TGF-b activated within microglial-neural interfaces to neighboring microglia. Overall, the results suggest that, when a V b 8 -bearing cells activate TGF-b1, it is released into a highly localized milieu where a V b 8 -bearing cells interface with microglia bearing proTGF-b1-LRRC33 complexes (Figure 7) . Once activated, TGF-b1 can bind to its receptors on either microglia (autocrine signaling) or other glial cells or neurons (paracrine signaling). Thus, our findings on a previously uncharacterized TGF-b milieu molecule support the hypothesis that TGF-b activation is highly localized in vivo. The association of milieu molecules with different in vivo functions of TGF-b opens up new approaches for therapy with antibodies or other antagonists that target proTGFb associated with specific milieu molecules.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
All animal experiments were approved by the Institutional Animal Care and Use Committees (IACUC) at Harvard Medical School and Boston Children's Hospital. C57BL/6N embryonic stem (ES) cells with the Lrrc33 gene inactivated by homologous recombination ( Figure S2A ) from UC Davis Knockout Mouse Project (KOMP) Repository (Project ID CSD40790) were injected into C57BL/6N blastocysts. Heterozygous C57BL/6N Lrrc33 +/À mice were fertile with no abnormalities and were used to breed Lrrc33 À/À mice. (Figures S2C and S2D ). Heterozygous mice were fertile but we obtained no evidence of Garp À/À viable or perinatally dead neonates.
METHOD DETAILS
Reagents
DNA constructs
Human GARP, proTGF-b1 and LTBP1 constructs for 293 cell transfection were described (Wang et al., 2012) . Human LRRC33 and mouse proTGF-b1 cDNAs were from Origene (Rockville, MD) and mouse LRRC33 cDNA from GE Dharmacon (Lafayette, CO). Human and mouse LRRC33 were subcloned into pLEXm_v1 vector, which is derived from the pLEXm vector (Aricescu et al., 2006) and contains a protein secretion signal peptide generated from Hidden Markov model (Barash et al., 2002) , followed by Flag tag. LRRC33 constructs with N-terminal Flag tag and secretion peptide were further subcloned into pcDNA3.1(+) vector (Invitrogen). Human LRRC33 was also subcloned into ET1 vector (Mi et al., 2008) , which contains C-terminal protein C tag. LRRC33 cysteine mutations were generated in ET1 vector using QuickChange (Stratagene). LRRC33 and GARP chimeras were constructed by overlap PCR and cloned into pEF1-puro (Dong et al., 2017) . Unconjugated anti-mouse TGF-b1 prodomain (TW7-16B4) and anti-human TGF-b1 prodomain (TW4-2F8) (Oida and Weiner, 2010) ) were generously provided by Dr. Howard Weiner. Hamster monoclonal antibody to denatured mouse LRRC33/NRROS (Noubade et al., 2014) was provided by Genentech. Secondary antibodies included APC or Alexa 488 or 546-labeled goat anti-mouse, anti-rat or anti-rabbit IgG (Invitrogen), HRP conjugated sheep anti-mouse IgG, goat anti-rabbit IgG and rabbit anti-goat IgG (GE Healthcare), and HRP-goat anti-hamster IgG (Jackson Laboratory). HRP-streptavidin was from GE Healthcare. 17E6 Mab to a V integrin (Mitjans et al., 1995) was from E. Merck, Darmstadt, Germany. MAB240 to TGF-b1 was from R&D Systems. 7.1G10 to integrin b6 (Weinreb et al., 2004) was from Biogen, Cambridge, MA. Binding proteins to aVb6 or aVb8 (b6+b8_BP and b8_BP) and b8 antibody ADWA-2 (Sheppard et al., 2014) were measured for affinity using K562 transfectants overexpressing human integrin aVb6 or aVb8. Cells were incubated with ADWA-2 or biotinylated binding proteins at a range of concentrations, followed by incubation with fluorophore labeled secondary antibody or streptavidin, and subjected to fluorescence flow cytometry. ADWA-2 is aVb8-specific and binds with a K d of 0.6 ± 0.1 nM. The K d of b6+b8_BP is 1.7 ± 0.2 nM with aVb6 and 7.3 ± 1.4 nM with aVb8. The K d of b6_BP is 0.11 ± 0.09 nM with aVb6 and 580 ± 40 nM with aVb8. LRRC33 monoclonal antibody (mAb) LRRC33 mAb was generated by immunizing Lrrc33 À/À mice with L1.2 transfectants that stably expressed the 33-G-X1 chimera, which contains the N-terminal 188 amino acids of LRRC33. Mice were immunized once intraperitoneally with 10 7 cells and boosted intravenously with transfectants 3 days before fusion. Splenocytes from two immunized mice were fused with P3X63Ag8.653 myeloma cells (Springer, 1980) . Hybridoma supernatants were screened by immunofluorescence flow cytometry. An LRRC33 positive hybridoma was identified that stained 33-G-X1 chimera but not GARP transfectants (Figures S1A and S1B). Clone 1/8.8 (IgG3, lambda) recognizes human LRRC33 in permeabilized 293T transfectants (not shown) and on the surface of human myeloid THP-1 cells ( Figure 2F ), immunoprecipitates human LRRC33 complexed with proTGF-b1 from cell lysates of co-transfectants, and does not crossreact with mouse LRRC33 complexes ( Figure S1C ). 1/8.8 VH and VL sequences were used to make a recombinant mouse IgG1 antibody, 1/8.8R, which was expressed in Expi293F cells. 1/8.8R exhibited the same specificity in immunofluorescent flow cytometry and immunoprecipitation as 1/8.8; however, 1/8.8 was more potent in blocking TGF-b activation, suggesting a role for the IgG3 subclass in functional assays.
Mouse experiments X-Gal staining
Lrrc33
+/lacZ , Garp +/lacZ and WT 3-month old mice were euthanized and transcardially perfused with ice cold PBS. Organs were removed, fixed with 2% paraformaldehyde, stained overnight at 37 C with 1 mg/ml X-gal (Sigma B4252), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl 2 , in PBS pH 7.4, and washed 5 times with PBS.
Scoring neurological symptoms
A 5-point clinical score was used for Lrrc33 knockout mice with 1 point each for loss of hind limb grasp, loss of bladder control, loss of coordination leading to hind limb paraplegia, inability to walk upright, and full quadriplegia (requiring euthanasia). SHIRPA tests (Rogers et al., 1997) Cell isolation, sorting, transfection, TGF-b assay, and microarrays Isolation, sorting, and culture of mouse cells For peritoneal exudate cell (PEC) macrophages, mice were injected with 1 mL of 4% thioglycollate medium. After 4 days, PEC were collected by lavage using 10 mL PBS. Cells were used directly for WB or IP, or allowed to adhere for 24 hours in 6 well plates to isolate macrophages. Cell suspensions enriched in microglia were obtained from brains of 21-day-old, transcardially perfused mice as described (Lee and Tansey, 2013 ) using 330 units of papain (Worthington) per brain. Cells that sedimented through a cushion of 37% Percoll were then analyzed or purified further. For 8-month-old mice, brain cell suspensions were prepared by Dounce homogenization instead of papain digestion, and microglia enriched using an otherwise identical procedure. For purification by sorting for RNA preparation or analysis by flow cytometry, microglia were labeled with antibodies to CD45 (APC-CD45.2, clone 30-F11; or APC-Cy7-CD45.1, clone A20, Biolegend), Mac1 (PE-Cy7-Mac1, clone M1/70, Biolegend), CD39 (PE-CD39, clone 5F2, Biolegend), and CD68 (Alexa488-CD68, FA-11, Biolegend). In some experiments (with CD68 and for isolation of mRNA), APC-Cy7-Ter-119 (Biolegend) was also used. In flow cytometry, the first gates used were scatter (side versus forward scatter), singlets (peak intensity versus area under the curve of forward scatter), and live cells (propidium iodide).
RNaseq data shown in Figure 1H is from (Zhang et al., 2014) and quantitative values for the genes used in Figure 1H are shown in Supplemental dataset 1. Microarray analysis Euthanized mice were perfused to minimize possible contamination with monocytes, macrophages, and other blood cells. FACSsorted microglia (CD45 low CD11b + CD39 + Ter119 -propidium iodide -) were isolated from 3-week old mice as described in the previous paragraph. Total RNA was isolated using Trizol (Invitrogen) according to the manufacturer's protocol. RNA preps with sufficient quality and integrity as verified using a Bioanalyzer 2100 (Agilent Technologies) were hybridized with Affymetrix Mouse Exon 1.0 ST arrays at the Molecular Biology Core Facilities of the Dana-Farber Cancer Institute. Arrays were processed using the BioConductor oligo package (Carvalho and Irizarry, 2010) and normalized using RMA (Irizarry et al., 2003) to provide expression summaries at the exon level. Quality was assessed with the Bioconductor array QualityMetrics package. Affymetrix annotation files were used to collapse probe sets to the 'core' set of annotations and summarize the expression data at the gene level, which was used as input for differential expression analysis (Data S2). Significantly different genes were identified using limma (Smyth et al., 2005) . GSEA (Subramanian et al., 2005) was carried out on the full expression data matrix with the ''hallmark (H)'' gene sets database, which represents 50 specific well-defined biological states or processes. Microglia and astrocytes Microglia were isolated from 3-week old mice as described in the previous section. Microglia were purified by immuno-panning (Zhang et al., 2014 ) with a polyclonal CD45 antibody (catalog #AF114; R&D systems). Prior to co-culture, microglia were cultured for 5 days with no change of medium at 37 C, 5% CO 2 in 6-well poly-D-lysine-coated plates in Neurobasal medium with B-27 Supplement (Thermo Fisher), 5 mg/ml insulin, 2 mM L-glutamine, 1 mM sodium pyruvate, 5 mg/ml N-acetyl cysteine, 100 U/ml penicillin, 100 mg/ml streptomycin, 10 mM thyroxine, 100 mg/ml transferrin, 100 mg/ml BSA, 16 mg/ml putrescine, 60 ng /ml progesterone, 40 ng/ml sodium selenite (Sigma) and 10 ng/ml mouse recombinant, carrier-free colony stimulating factor (R&D Systems) (serumfree microglia culture medium).
Astrocytes were isolated from the cerebrum and cultured as described (McCarthy and de Vellis, 1980) . For microglia and astrocyte co-culture, microglia and astrocytes (2x10 4 cells of each/well) were added in 200 mL to 48-well poly-D-lysine-coated plates and cultured in serum-free microglia culture medium containing 10 ng/ml heparin-binding EGF-like growth factor at 37 C in 5% CO 2 for 7 days. Culture and transfection of cell lines 293T cells were maintained in DMEM medium with 10% FBS, transfected with the indicated plasmid(s) using Lipofectamine 2000 (Life Technologies) according to manufacturer's instructions, and analyzed 48 hours later. THP-1 and L1.2 cells were maintained in RPMI-1640 medium with 10% FBS. L1.2 cells (10 7 ) were transfected with 20 mg linearized plasmid DNA by electroporation at 250 V, 960 mF (Gene Pulser, Bio-RAD). After 48 hours, 2 mg/ml puromycin or 500 mg/ml G418 was added for selection. Transfectants were further subcloned by limiting dilution, and clones with surface expression confirmed by flow cytometry using antibodies to Flag tag and proTGF-b1 were expanded and used for experiments.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis GraphPad Prism 6 software (La Jolla, CA) was used for statistical tests including unpaired Student's t test and log-rank (Mantel-Cox) test and data are presented as mean ± SEM. No statistical methods were used to pre-determine sample sizes. However, our sample sizes are similar to those in previous publications (Zhang et al., 2014) . Data collection and analysis were performed blinded to conditions in all experiments. A p value of less than 0.05 was considered as significant.
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